Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Staging of Heart Failure with Preserved Ejection Fraction
Author(s): Anastasia Shchendrygina , Ilya Giverts , Mariya Tokmakova , et al Added: 6 months ago

Imaging & Diagnostics

Heart Failure
HFSA 24: FINEARTS-HF Across the Ejection Fraction Spectrum
Author(s): Akshay S Desai Added: 7 months ago
HFSA 24 - Dr Akshay Desai (Brigham and Women’s Hospital, US) sits down with us to discuss the findings from FINEARTS-HF across the ejection fraction spectrum in heart failure with mildly reduced and preserved ejection fraction.Interview Questions:1. What was the reasoning behind this study? What was the study design and patient population?2. What was the study design and patient population?3… View more

Heart Failure
HFA 23: DAPA-HF and DELIVER: KCCQ in Pts with Varying Ejection Fraction
Author(s): Ankeet Bhatt Added: 1 year ago
ESC-HFA 2023 - Dr Ankeet Bhatt (Kaiser Permanante San Francisco Medical Center, US) joins us onsite to discuss a study that looked into Kansas City Cardiomyopathy Questionnaire (KCCQ) scores in patients with varying ejection fractions, that were enrolled in the DELIVER and DAPA-HF trials. This study used pooled, patient-level data from the DAPA-HF and DELIVER studies, aiming to examine the… View more

Heart Failure
HFA 23: Trientine-HCL for Treatment of HFrEF
Author(s): James L Januzzi , Harriette Van Spall Added: 1 year ago
ESC-HFA 2023 - Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Dr James Januzzi (Massachusetts General Hospital, US) to discuss the findings of the TRACER-HF trial. Trientine-HCL is an oral chelation agent. Preclinical trials suggest that this promotes a reverse cardiac remodelling effect in HFrEF patients. 200 patients with New York Heart Association Class II or… View more

Heart Failure
HFA 24: The RELIEVE-HF Trial: Differential Effects of V-Wave Device
Author(s): Michael R Zile Added: 12 months ago
HFA 24 - We are joined onsite by Dr Michael Zile (Medical University of South Carolina, US) to discuss the outcomes of the RELIEVE-HF trial.RELIEVE-HF is designed to evaluate the safety and effectiveness of the V-Wave interatrial shunt system in patients with heart failure. 605 participants with New York Heart Association (NYHA) functional class II, class III or class IV heart failure, who had… View more

Heart Failure
EHRA 25: The European Affera Ventricular Arrhythmia Ablation Registry
Author(s): Frédéric Sacher Added: 1 month ago
EHRA 2025 - Positive safety results of the Affera mapping and ablation system for the treatment of ventricular arrhythmias (VA) show a 6% rate of major complication.Dr Frédéric Sacher (IHU Liryc, Bordeaux, FR) joins us on-site at EHRA Congress 2025 to discuss safety results from the European Affera Ventricular Arrhythmia Ablation Registry, investigating VA ablation with the Affera Sphere-9… View more

Electrophysiology & Arrhythmia
Cardiovascular Disease and Type 2 Diabetes
Author(s): Martin Berger , Nikolaus Marx , Katharina Marx-Schütt Added: 1 month ago

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
Left Atrium Role in Secondary Mitral Regurgitation
Author(s): Markos Koukos , Yannis Dimitroglou , Dimitrios Tsartsalis , et al Added: 1 year ago

Vascular Disease and Surgery

Imaging & Diagnostics
TCT 24: The EVOLVED Trial
Author(s): Marc Dweck Added: 6 months ago
TCT Conference 2024 - Clinical outcomes of early intervention in patients with asymptomatic aortic stenosis (AS) did not impact the composite primary outcome of all cause mortality and unplanned AS related hospitalisation.Dr Marc Dweck (University of Edinburgh, Edinburgh, UK) joins us in this short interview filmed onsite at TCT Conference to discuss the findings from EVOLVED (NCT03094143;… View more

Imaging & Diagnostics
Management of Left Main Coronary Artery Disease
Author(s): Gabriel Torres-Ruiz , Nuria Mallofré-Vila , Paola Rojas-Flores , et al Added: 1 year ago

Prevention & Chronic Conditions

Intervention